Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial
John M. Slopis(The University of Texas MD Anderson Cancer Center), Mary Kay Koenig, Cynthia Bell(World Health Organization - Pakistan), Octavio Arevalo(The University of Texas Health Science Center at Houston), Joshua Samuels(AstraZeneca (United Kingdom)), Hope Northrup(The University of Texas MD Anderson Cancer Center), Roy Riascos(The University of Texas Health Science Center at Houston), Adelaide A. Hebert(The University of Texas Health Science Center), Patti L. Pierce Tate(The University of Texas Health Science Center at Houston), Keri Csencsits‐Smith(The University of Texas Health Science Center at Houston)
Cited by 26
Related Papers
Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
|Pediatric Neurology|2013|1.5k
Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
|Pediatric Neurology|2013|863
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations
|Pediatric Neurology|2021|727
Point mutations in human keratin 14 genes of epidermolysis bullosa simplex patients: Genetic and functional analyses
|Cell|1991|656
Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society
|Genetics in Medicine|2014|605